Cerepro, 400 mg capsules 56 pcs

Pharmacotherapeutic group: nootropic
ATX code: [N07AX02]

Pharmacological Action

Central choline stimulant, which contains 40.5% metabolically protected choline (metabolic protection promotes choline release in the brain). Once in the body it is cleaved by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine – one of the main mediators of neural excitation; glycerophosphate is a precursor of phospholipids (phosphatidylcholine) of the neuronal membrane.

Provides synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of the traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular disease.

It improves brain function through its influence on pathogenetic factors of involutional psychoorganic syndrome, changes phospholipid membrane composition of neurons and reduces cholinergic activity. It dose-dependently stimulates acetylcholine release; participating in the synthesis of phosphahydylcholine (membrane phospholipid), improves synaptic transmission, neuronal membrane plasticity, receptor function. It does not influence reproductive cycle and is not teratogenic and mutagenic.

Pharmacokinetics.

Absorption – 88 %, easily penetrates through blood-brain barrier (concentration in brain in per oral administration is 45 % of that in plasma). It is excreted mainly by lungs in the form of carbon dioxide (85%), as well as by the kidneys and through the intestines (15%).

Indications

acute and recovery periods of severe traumatic brain injury and ischemic stroke, recovery period of hemorrhagic stroke, occurring with focal hemispheric symptoms or symptoms of brain stem damage;
psychoorganic syndrome against the background of degenerative and involutional changes in the brain;
chronic cerebrovascular insufficiency;
cognitive disorders (impaired mental function, memory, confusion, disorientation, decreased motivation, initiative and ability to concentrate), including dementia and encephalopathy.
senile pseudomelancholia.

Pharmacological effect

Pharmacotherapeutic group: nootropic agent
ATX code: [N07AX02]

Pharmacological action

Central anticholinergic stimulant, which contains 40.5% metabolically protected choline (metabolic protection promotes the release of choline in the brain). When it enters the body, it is broken down by enzymes into choline and glycerophosphate: choline is involved in the biosynthesis of acetylcholine, one of the main mediators of nervous excitation; glycerophosphate is a precursor to phospholipids (phosphatidylcholine) in the neuronal membrane.

Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear speed of blood flow on the side of the traumatic brain injury, helps to normalize the spatiotemporal characteristics of spontaneous bioelectrical activity of the brain; has a positive effect on the cognitive and behavioral reactions of patients with vascular diseases of the brain.

Improves brain function by influencing the pathogenetic factors of involutional psychoorganic syndrome, changes the phospholipid composition of neuron membranes and reduces cholinergic activity. Dose-dependently stimulates the release of acetylcholine; participating in the synthesis of phosphagidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, and receptor function. Does not affect the reproductive cycle and does not have teratogenic or mutagenic effects.
Pharmacokinetics.

Absorption – 88%), easily penetrates the blood-brain barrier (when taken orally, the concentration in the brain is 45%) of that in plasma). It is excreted primarily by the lungs, in the form of carbon dioxide (85%), as well as by the kidneys and intestines (15%).

Special instructions

If nausea occurs after taking the drug, the dose should be reduced.

Active ingredient

Choline alphoscerate

Composition

One capsule contains:

as an active substance 400 mg glycerylphosphorylcholine hydrate (choline alfoscerate);

excipients:

glycerol (glycerin),

purified water.

Capsule shell:

medical gelatin,

glycerol (glycerin),

methyl parahydroxybenzoate (methylparaben),

propyl parahydroxybenzoate (propylparaben),

iron oxide red dye,

titanium dioxide,

purified water,

sorbitol (sorbitol).

Contraindications

Hypersensitivity, pregnancy, breastfeeding.

Side Effects

Allergic reactions, nausea (due to dopaminergic activation).

Interaction

Not identified.

Overdose

Symptoms: dyspeptic disorders.

Storage conditions

In a dry place, protected from light and out of reach of children, at a temperature of 25°C.

Shelf life

2 years.

Manufacturer

Veropharm LLC, Russia